GSK plc (GSK) Stock Price & Analysis
Market: NYSE • Sector: Healthcare • Industry: Drug Manufacturers - General
GSK plc (GSK) Profile & Business Summary
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development; two strategic collaborations with Relation to advance therapeutics for fibrotic diseases and osteoarthritis; and multi-target strategic alliance with GSK to develop breakthrough treatments for people afflicted with Parkinson's disease; as well as collaboration with Flagship Pioneering to discover novel medicines and vaccines. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.dom.
Key Information
| Ticker | GSK |
|---|---|
| Exchange | NYSE |
| Official Site | https://www.gsk.com |
Market Trend Overview for GSK
One model, two time views: what the market looks like right now, and where the larger trend is heading over time.
SRE (WhaleQuant Structural Regime Engine) SRE evaluates how price structure evolves across daily and weekly timeframes to define the prevailing market regime. Beyond identifying trends, consolidations, and exhaustion phases, it distinguishes between raw structural strength and deployable participation quality. The model dynamically adjusts for structural context and extension risk, assessing whether conditions are supportive, stretched, fragile, or structurally impaired. Its purpose is not to forecast precise price levels, but to determine whether risk deployment is aligned with underlying market structure.
Longer-Term Market Trend (Mid to Long Term)
Shows the bigger market trend, how strong it is, and where risks may start to build over the next few weeks or months. — Updated as of 2026-10-13 (ET)
As of 2026-10-13, GSK is showing signs of slowing down. Over the longer term, the trend remains bullish.
GSK last closed at 46.27. The price is about 0.6 ATR below its recent average price (47.00), and the market is currently in a trend that may be losing strength. Price at 46.27 is near minor support around 45.83. Momentum may slow, while minor resistance sits near 47.41. View Support & Resistance from Options
Short-term weakness is unfolding within a broader uptrend, suggesting a pullback rather than a full trend reversal.
Trend score: 55 out of 100. Overall alignment is unclear. The market is currently in a late-stage trend that may be losing strength. The longer-term trend is still positive, but short-term signals are not yet confirming it.
There is no clear key risk boundary right now.
On 2026-09-23, trend conditions deteriorated, suggesting that moves in the prior direction became less dependable.
[2026-09-11] Price moved quickly and looked strong, but participation was limited.
Recent bars show mixed price behavior without a clear shift in structural quality or efficiency.
There was no clear sign of meaningful positions being carried into the overnight session.
The model stays neutral because the setup is not clear enough to justify a directional deployment.
The model does not issue an actionable directional forecast. Predictability is 43%, agreement is 83%, and reversal risk is 18%.
NOTE: This next-day up/down probability forecast module is still being tested for accuracy. Please do not rely on it for investment decisions. The model does not account for black swan events or company-specific fundamental news, and its estimates are based solely on technical conditions, capital flow, and market sentiment. View forecast history
This estimate uses 1-minute price, volume, and VWAP data from the last 58 trading days, with turnover-based decay. The sample period is 2026-07-23 to 2026-10-13. The current price is 46.27, 6.57% below the estimated average cost of 49.52. An estimated 3.4% of recent positioning is below the current price, while 95.8% is above it. The peak-density price is 46.55. The largest concentrated cost region is 46.08 to 47.12 and contains 29.2% of the estimated distribution. The current price is within the 46.08 to 47.12 cost region. The nearest region above the current price is 48.58 to 48.68.
Short Interest & Covering Risk for GSK
This analysis looks at overall short interest positioning, focusing on the broader setup rather than short-term noise.
Shows how likely a short squeeze may be under current market conditions.
Short Exposure Percentile
Short interest is above its usual range, suggesting rising pressure on short positions, though not yet extreme. (Historical percentile: 66%)
Structure Analysis
GSK Short positioning looks normal. Current days to cover is 4.1 trading days, meaning short positions could unwind at a normal pace. Short covering is likely to have a normal impact on price moves. Price is already trending lower (20D return -7.5%). The current configuration reflects active downside pressure rather than latent structural fragility.
Risk Summary
No clear bull trap characteristics detected. Recent price behavior remains broadly consistent with current positioning.This reading helps confirm that current price action remains structurally healthy and does not indicate elevated trap risk.
Why Price Reactions May Be Stronger?
Days-to-Cover is elevated versus its own history, but absolute short interest remains moderate. In the latest reporting period, short interest continues to increase. Adaptive thresholds applied to liquidity weakness, near-high detection, and compression sensitivity. As a result, similar news or market events could lead to price moves about 2× larger than usual.
Note:
Short interest data is reported every two weeks by
FINRA.
The most recent snapshot is
2026-09-30 (ET).
Because this data updates slowly, it is not intended to predict short-term price moves. Instead, it helps describe longer-term market structure and where pressure may be building if prices begin to move.